knowledge -WSS

knowledge

author：hotspot 2025-09-29 21:14:57 - browse：3124

Photo illustration based on photograph of The University of Texas MD Anderson Cancer Center in Houston, Texas in 2022 — Photo illustration: STAT; Photo: Adobe

Prominent immunologist and oncologist Padmanee Sharma defended herself in court on Friday against a lawsuit that alleges she threatened to undermine a junior faculty member’s career, made defamatory comments about the younger scientist, and attempted to take credit for work that she didn’t do.

In legal filings submitted to the Harris County District Court, Sharma said that she made substantial contributions to an immunotherapy project that were ignored, and that a third-party assessment commissioned by MD Anderson Cancer Center concluded Sharma should be given credit for her role. Sharma had previously issued a general denial of the allegations against her and claimed immunity from the suit as a government employee. As part of the University of Texas, MD Anderson is a state institution.

The filing, which was submitted by Texas Attorney General Ken Paxton and lawyers in his office, also argued that the junior researcher’s lawsuit should be made against MD Anderson, not Sharma, and asked the court to dismiss the suit if it is not amended within 30 days. “Dr. Sharma is not a proper party to this lawsuit; only MDACC is,” the filing states. “This lawsuit is about proper accreditation in scientific literature for research performed at MDACC by MDACC faculty.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Results on Novartis prostate cancer therapy could expand its use

WSS

STAT Summit: Meghan O’Rourke on making chronic illness visible

Private equity could exacerbate cardiology's overuse problem, experts fear

Study on Amgen’s bispecific immunotherapy produces positive data

STAT Summit: The economic case for universal basic health care

How to make the FDA’s new prescription one

How to make the FDA’s new prescription one

entertainment

knowledge

hotspot

Peter Hotez and the public health issue of online harassment

Results on Novartis prostate cancer therapy could expand its use

United colonoscopy coverage change 'may cost lives,' doctors say

FDA proposes changes to key medical devices approval pathway

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Health tech investors get more selective as pandemic boom fades

State Dept. review finds Biden bears some blame for Afghanistan failures

STAT Summit: The economic case for universal basic health care

Duchenne breakthrough therapy leaves behind pioneering families

Is there really a nursing shortage in the U.S.?

Wikipedia

Diverse clinical trials: Why aren’t we there yet?

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

Health tech investors get more selective as pandemic boom fades

STAT Readout: Friday, Oct. 20 biotech updates

Cassava Sciences’ Alzheimer’s clinical trials should be halted

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Wikipedia

focus

focus

focus